Shares of Ultragenyx Pharmaceutical Inc. (RARE) touched a new high on Thursday, following positive interim data from the first 12 patients in the ongoing pediatric phase II study of its recombinant human monoclonal antibody KRN23 against fibroblast growth factor 23 (FGF23) for the treatment of X-linked hypophosphatemia (XLH).